WASSIL NOWICKY
Nowicky Pharma/Ukrainian Anti-Cancer Institute, Austria
Biography
Wassil Nowicky (Dipl Ing, Dr techn, DDD rh c) is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955; with graduation to Diplomingeniueur in 1960 which title was nostrificated in Austria (1975). He became the very first Scientist in the development of the anticancer protonic therapy and is the Inventor of NSC-631570, the anticancer preparation on basis of celandine alkaloids. He used the factor that cancer cells are more negatively charged than normal cells and invented the celandine alkaloid with a positive charge, thanks to which it accumulates in cancer cells very fast. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real Member of the New York Academy of Sciences, Member of the European Union for applied immunology and of the American Association for scientific progress, honorary Doctor of the Yanka Kupala State University of Grodno, Doctor honoris causa of the Open International University for Complementary Medicine in Colombo, Honorary Member of the Austrian Society on the Name of Albert Schweizer. He has received merits of National Guild of the award of Austrian Society of sanitary, hygiene and public health services and others.
Abstract
It is well known that all cells possess the negative charge and cancer cells have a much more negative charge than normal cells. This property has been used for the creation of the anticancer preparation on basis of greater celandine alkaloids with the positive charge. The experiment has been carried out on basis of the sum of greater celandine alkaloids as well as on basis of the pure chelidonine with the aim to understand the mechanism of action of the preparation NSC 631570. Chelidonine is the tertiary alkaloid and it doesn’t have the property to fluoresce. After its transformation into the quartet alkaloid it becomes a proton, accumulate in cancer tumors very fast and becomes visible, thanks to its auto-fluorescence. Until now, this preparation has been tested on over 100 cancer cell lines and on 12 normal cell lines and the results of the studies carried out in more than 120 universities and research centers (in particular at the National Cancer Institute (the USA)) have shown that the NSC 631570 killed only cancer cells without damaging the normal cells which confirmed its selective effect. In clinical trials, it also has proved its anticancer efficacy and caused no noteworthy side effects. The results of in vitro studies also have shown the direct deletion of cancer cells and its ability to regenerate the immune system. Such a property is unusual for an anticancer agent but as it can be seen the NSC 631570 possesses some distinct immune properties. In several immune target-effector systems NSC 631570 significantly amplified the malignotoxic activity of macrophages, lymphocytes and NK cells, and stimulates dendritic cells maturation in vitro. While the parameters like B-lymphocyte count, immune globulin concentrations, complement and acute phase proteins did not changed significantly, it can be postulated that NSC 631570 modulates the cellular part of the immune system whereas the humoral part remains unaffected. The aim of the presentation is to pay attention of the scientific world on the selective and immunomodulating effects of the very first proton anticancer preparation, NSC 631570.